Синтез пептидомиметиков — ингибиторов сериновых протеиназ

Список литературы

1. Fenton J.W. Regulation of thrombin generation and functions. // Semin. Thromb. Haemost. 1988. v. 14. p.234−240.
2. Stubbs M.T., Bode W. A player of many parts: the spotlight fallson thrombin’s structure. // Thromb. Res. 1993. v.69 p.1−58.
3. Blomback B. Fibrinogen and fibrin proteins with complex roles in haemostasisand thrombosis. // Thromb. Res. 1996. v.83 p. 1−75.
4. Davie E.W., Fujikawa K., Kisiel W. The coagulation cascade: initiation, maintenance and regulation. // Biochemistry. 1991. v.30. p.10 364−10 370.
5. Esmon C.T. The roles of protein С and thrombovodulin in the regulation of blood coagulation. //J. Biol. Chem. 1989. v.264. p.4743−4746.
6. Levin E.G., Stern D.M., Nawroth P.P., Marlar R.A., Fair D.S., Fenton J.W., Harker L.A. Specificity of the thrombin-induced earelse of tissue plasminogen-activator from cultured human endothelial cells. // Thromb. Haemost. 1986. v.56. p. 115−119.
7. Moon D.G., Horgarn M.J., Anderson T.T., Krystek S.R., Fenton J.W., Malik A.B. Endothelial-like pulmonary vasoconstrictor peptide release by a-thrombin. // Proc. Natl. Acad. Sci. USA. 1989. v.86. p.9529−9533.
8. Березов T.T., Коровкин Б. Ф. Биологическая химия. // Под ред. Академика АМН СССР Дебова С. С. Москва. «Медицина». 1990. с.439−446.
9. Castellino F. J. Recent advances in the chemistry of the fibrinolytic system. // Chem. Rev. 1981. v. 81. N5. p.431−446.
10. Bjork I., Lindahl V. Mechanism of the anticoagulant action of heparin. // Mol. Cell. Biochem. 1982. v.48. p. 161−182.
11. Parker K.A., Tollefsen D.M. The protease specificity of heparin cofactor II: inhibition of thrombin generated during coagulation. // J. Biol. Chem. 1985. v.260. p.3501.
12. Olson S.T., Shore J.D. Demonstration of a two-step reaction mechanism for inhibition of a-thrombin III and idendification of the step affected ЬЗЗЗу heparin. // J. Biol. Chem. 1982. v.257. p. 14 891−14 895.
13. Stone S.R., Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. // Biochemistry. 1986. v.25. p.4622−4628.
14. Markward F. The development of hirudin as an antithrombotic drug. // Thromb. Res. 1994. v.74. p. 1−23
15. Qiu X., Yin M. Padmanabhan K.P., Krstenansky J.L., Tulinsky A. Structures of thrombin complexes with a designed and a natural exosite peptide inhibitor. //J. Biol. Chem. 1993. v.268. p.20 318−20 326.
16. Модифицированные аминокислоты и пептиды на их основе. Под редакцией ЧипенсаГ.И. // Рига: Зинанте. 1987. с. 214.
17. Aoyagi Т., Takeuchi Т., Matsuzaki A., Kawamura К., Kondo S., Hamada М., Maeda К., Umezawa Н. Leupeptins, new protease inhibitors from actinomycetes. //J. Antibiotics. 1969. v.22. p.283−286
18. Kondo S., Kawamura K., Iwamaga J. Hamada M., Aoyagi Т., Maeda K., Takeuchi Т., Umezawa H. Isolation and characterization of leupeptins produced by actinomycetes. // Chem. Pharm. Bull. 1969. v. 17. p. 18 961 901.
19. Maeda K., Umezawa H. Synthetic studies on leupeptins and their analogs. //J. Antibiotics. 1972. v.25. p.515−523.
20. Aoyagi Т., Miyata S., Takeuchi Т., Umezawa H. Biological activities of leupeptins. //J. Antibiotics. 1969. v.22. p.558−568.
21. Kamiyama Т., Umino Т., Nakamura Y., Itezono I., Sawairi S., Satoh Т., Yokose K. Bacithrocins А, В and C, novel thrombin inhibitors. // J. Antibiotics. 1994. v.47. p.959−968.
22. Maraganore J.M., Bourdon P., Jabloncky J., Ramachandran K.L., Fenton J.W. Design and characterization of girulogs: a novel class of divalent peptide inhibitors of thrombin. // Biochemistry. 1990. v.29. p.7095−7101.
23. Naski M.C., Fenton J.W., Maraganore J.M., Oslon S.T., Shafer J.A. The COOH-terminal domain of hirudin. // J. Biol. Chem. 1990. v.265. p.13 484−13 489.t
24. Lombardi A., Nastri F., Morte R.D., Rossi A., De Rosa A., Ataiano N., Pedone C., Pavone V. Rational design of true hirudin mimetics: synthesis and characterization of multisite-directed a-thrombin inhibitors. // J. Med. Chem. 1996. v.39. p.2008−2017.
25. Maraganore J.M., Chao B., Joseph M.L., Jablonski J., Ramachandran K.L. Anticoagulant activity of synthetic hirudin peptides. // J. Biol. Chem. 1989. v.264. p.8692−8698.
26. DiMaio J., Gibbs B., Munn D., Lefebre J., Ni F., iConishi Y. Bifunctional thrombin inhibitors based on the sequence of hirudin 45−65. // J. Biol. Chem. 1990. v.265. p.21 698−21 703.
27. Nienaber V.L., Amparo E.C. A non-cleavable retro-binding peptide that spans the substrate binding cleft of serine protease. Atomic structure of nazumamide A: human thrombin. // J. Am. Chem. Soc. 1996. v. 118. p.6807−6810.
28. Tabernero L., Chang C.Y.Y., Ohringer S.L., Lau W.F., Iwanowcz E.J., Han W., Wang T.C., Seiler S.M., Roberts D.G.M., Sack J.S. Structure of a retro-binding peptide-inhibitor complexed with human a-thrombin. // J. Mol. Biol. 1995. v.246. p. 14−20.
29. Lewis S.D., Ni A.S., Baldwin J.J., Fusetani N., Naylor A.M., Shafer J.A. Inhibition of thrombin and other trypsin-like serine proteinases by cyclotheonamide A. // Thromb. Res. 1993. v.70. p. 173−190.
30. Bock L.C., Griffin L.C., Latham J.A., Vermaas E.H., Toole J.J. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. //Nature. 1992. v.355. p.564−566.
31. Paborsky L.R., McCurdy S., Griffin L.C., Toole J.J., Leung L.L.K. The single-stranded DNA aptamer-binding site of human thrombin. // J. Biol. Chem. 1993. v.268. p.20 808−20 811.
32. Kubik M.F., Stephens A.W., Schneider D., Marlar R., Tasset D. High-affinity RNA ligands to human a-thrombin. // Nucleic Acids Res. 1994. v.22. p.2619−2626.
33. Hauptmann J., Sturzebercher J. Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. // Thromb. Res. 1999. v.93. p.203−241.
34. Fareed J., Callas D.D., Hoppensteadt D., Jeske W., Walenga J.M. Recent developments in antithrombotic agents. // Exp. Opin. Invest. Drugs. 1995. v.4. p.389−412.
35. Callas D.D., Fareed J. Comparative pharmacology of site-directed antithrombin agents. Implication in drug development. // Thrombosis and Haemostasis. 1995. v.74. p.473−481.
36. Callas D.D., Iqbal O., Hoppensteadt D., Fareed J. Fibrinolytic compromise by synthetic and recombinant thrombin inhibitors: implications in the treatment of thrombotic disorders. // Clin. Appl. Thrombosis and Haemostasis. 1995. v.l. p. l 14−124.
37. Hauptmann J., Markwardt F. Pharmacologic aspects of the development of selective synthetic thrombin inhibitors as anticoagulants. // Seminars in thrombosis and haemostasis. 1992. v. 18. p.200−217. '
38. Bagdy D., Barabas E., Sebastyen I., Dioszegi M., Fittler Zs., Baiusz S., Szell E. Correlation between the anticoagulant and antiplatelet effect of D-Phe-Pro-Arg-H. //Thromb. Haemost. 1987. v.58. p.177−186.
39. Bagdy D., Barabas E., Szabo G., Bajusz S., Szell E. In vivo anticoagulant and antiplatelet effect of D-Phe-Pro-Arg-H and D-MePhe-Pro-Arg-H. // Thromb. Haemost. 1992. v.67. p.357−365.
40. Bajusz S., Barabas E., Szell E., Bagdy D. Inhibition of thrombin and trypsin by tripeptide aldehydes. // Int. J. Protein. Res. 1978. v. 12. p.217−221.
41. Bagdy D., Barabas E., Bajusz S., Szell E. In vitro inhibition of blood coagulation by tripeptide aldehydes a retrospective screening study focused on the stable D-MePhe-Pro-Arg-H*H2S04. // Thromb. Haemost. 1992. v.67. p.325−330.
42. Bajusz S. Interaction of trypsin-like enzymes with small inhibitors. // Symposia Biologica Hungarica. 1984. v.25. p.277−295.
43. Kettner C., Shaw E. D-Phe-Pro-ArgCH2Cl a selective affinity label for thrombin. // Thromb. Res. 1979. v. 14. p.969−973.
44. Lijnen H.R., Uyterhoeven M., Collen D. Inhibition of trypsin-like serine proteinases by tripeptide arginyl and lysyl chloromethylketones. // Thromb. Res. 1984. v.34. p.431−437.
45. Hauptmann J., Markwardt F. Studies on the coagulant and antithrombotic action of an irreversible thrombin inhibitor. // Thromb. Res. 1980. v.20. p.347−351.
46. Collen D., Matsuo O., Stassen J.M., Kettner C., Shaw E. In vitro studies of a synthetic inhibitor of thrombin. // J. Lab. Clin. Med. 1982. v.99. p.76−83.
47. Stuber W., Kosina H., Heinburger N. Synthesis of a tripeptide with a C-terminal nitrile moiety and the inhibition of proteinases. // Int. J. Pept. Protein Res. 1988. v.31. p.63−70.
48. Neises B., Tarnus C. Trombin inhibition by the tripeptide trifluoromethylketone D-Phe-Pro-ArgCH2CF3 (MDL73756). // Thromb. Haemost. 1991. v.65. p. 1290.
49. Cheng L., Scully M.F., Goodwin C.A. Peptide a-aminophophonic acids: a new type of thrombin inhibitor. // Thromb. Haemost. 1991. v.65. p. 1289.
50. Kettner C., Mesinger L., Knabb R. The selective inhibition of thrombin by peptides of boroarginine. //J. Biol. Chem. 1990. v.265. p. 18 289−18 297.
51. Cacciola J., Fevig J.M., Alexander R.S., Brittelli D.R. Synthesis of conformationally-restricted boropeptide thrombin inhibitors. // Bioorg. Med. Chem. Lett. 1996. v.6. p.301−306.
52. Tapparelli C., Metternich R., Ehrhardt C., Claeson G., Scully M.F., Stone S.R. In vivo and in vitro characterization of a neutral boron-containing thrombin inhibitor. // J. Biol. Chem. 1993. v.268. p.4734−4731.
53. Wienand A., Ehrhardt C., Metternich R., Tapparelli C. Design, synthesis and biological evaluation of selective boron-containing thrombin inhibitors. // Bioorg. Med. Chem. 1999. v.7. p. 1295−1307.
54. Hijikata-Okonomiya A., Okamoto S. A strategy for a rational approach to design synthetic selective inhibitors. // Seminars in thrombosis and haemostasis. 1992. v.18. p.135−149.
55. Morishita K., Iwamoto M. Synergistic antithrombotic effects of argatroban and ticlopidine in the rat venous thrombosis model a small-molecule, direct thrombin inhibitor. //Thromb. Res. 1998. v.92. p.261−266.
56. Sakai M., Ohteki H., Narita I., Naitoh K., Natsuaki M., Itoh T. Argatroban as a potential anticoagulant in cardiopulmonary bypass studies in a dog model. // Cardiovascular Surgery. 1999. v.7. p. 187−194.
57. Markwardt F., Wagner G., Sturzebercher J., Walsmann P. Na-arylsulfonyl-o)-(4-amidinophenyl)-a-aminoalkylcarboxylic amides novel selective inhibitors of thrombin. // Thromb. Res. 1980. v. 17. p.425−431.
58. Hauptmann J. Pharmacology of benzamidine-type thrombin inhibitors. // Folia Haemotol (Leipz.) 1982. v. 109. p. 118−123.
59. Sturzebercher J., Markwardt F., Voigt B., Wagner G., Walsmann P. Cyclic amides of Na-arylsulfonylaminoacylated 4-amidinophenylalanine tight binding inhibitors of thrombin. // Thromb. Haemost. 1983. v.29. p.635−642.
60. Claeson G., Gustavsson S., Mattsson C. New derivatives of p-guanidinophenylalanine as potent reversible inhibitors of thrombin. // Thromb. Haemost. 1983. v.50. p.53−58.109
61. Oweida S.W., Ku D.N., Lamsden A.B., Kam C.M., Powers J.C. In vivo determination of the anticoagulant effect of a substituted isocoumarin (ACITIC). //Thromb. Res. 1990. v.58. p.191−197.
62. Pizzo S.V., Turner A.D., Porter N.A., Gonias S.I. Evaluation of p-amidinophenyl esters as potential antithrombotic agents. Thromb. Haemost. 1986. v.56. p.387−390.
63. Ascenzi P., Gallina C., Bolognesi M. Thrombin inhibition by highly selective 'revercible suicide substrate' N-ethoxycarbonyl-D-phenylalanyl-L-prolyl-a-azalysine p-nitrophenyl ester. // Protein Pept. Lett. 2005. v.5. p.433−438.
64. Бумблите И. А. Ингибиторы плазмина. // Гематологическая трансфузиология. 1992. т.37. с.26−28.
65. Matsuzaki К., Matsui К., Tanoue Y., Nagano I., Haraguchi N., Tatewaki H. Antifibrinolytic therapy with tranexamic acid in cardiac operations. // Cardiovascular Surgery. 1999. v.7. p. 195−199.
66. Harpel P.C. Plasmin inhibitor interactions. The effectiveness of a2-plasmin inhibitor in the presence of a2-macroglobulin. // J. Exp. Med. 1977. v. 146. p. 1033−1040.
67. Lee K.N., Jackson K.W., Terzyan S., Christiansen V.J., McKee P.A. Using substrate specificity of antiplasmin-cleaving enzyme for fibroblast activation protein inhibitor design. // Biochemistry. 2009. v.23. p.5149−5158.
68. McConnell R.S., York J.L., Frizzel D., Ezzell C. Inhibition studies of some serine and thiol proteinases by new leupeptin analogues. // J. Med. Chem. 1993. v.36. p. 1084−1089.
69. Livingston D. In vitro and in vivo studies of ICE inhibitors. // J. Cell. Biochem. 1997. v.64. p. 19−26.
70. Thopmpson R.C. User of peptide aldehydes to generate transition state analogs of elastase. // Biochemistry. 1973. v. 12. p.47−51.
71. Dobson G., Wlodawer A. Catalytic triads and their relatives. // Trends. Biochem. Sci. 1998. v.23. p.347−352.
72. Степанов B.M. Молекулярная биология. Структура и функции белков. // Под ред. Спирина А. С. Москва. Высшая школа. 1996. с.203−233.
73. Uoet D., Uoet J.G. Biochemistry. // New York. J. Wiley & Sons, Inc. 1995.
74. Potetinova J.V., Milgotina E.I., Makarov V.A., Voyushina T.L. // Russ. J. Bioorg. Chem. 2001. v.3. p.141.
75. Потетинова Ж.В. Стратегия биокаталитического синтеза модифицированных пептидов ингибиторов протеиназ. // Дисс. канд. хим. наук. Москва. 2000.
76. Lynas J.Р., Martin S.L., Walker В. Synthesis and kinetic evaluation of peptide a-keto-P-aldehyde-based inhibitors of trypsin-like proteases. // J. Pharm. Pharmacol. 2001. v.4. p.473−480.
77. Garrett G.S., McPhail S.J., Tornheim K., Correa P.E., Mclver J.M. Synthesis of potent and selective inhibitors of human plasma kallikrein. // Bioorg. Med. Chem. Lett. 1999. v.9. p.301−306.
78. Teno N., Wanaka K., Okada Y., Tsuda Y., Okamoto U., Hijikata-Okunomiya A., Naito T., Okamoto S. Development of center-directed inhibitors against plasmin. // Chem. Pharm. Bull. 1991. v.39. p.2340−2346.
79. Sanders T.C., Seto C.T. 4-heterocyclohexanone-based inhibitors of the serine proteinase plasmin. // J. Med. Chem. 1999. v.42. p.2969−2976.
80. Hovhannisyan N., Harutyunyan S., Hovhannisyan A., Hambardzumyan A., Chitchyan M., Melkumyan M., Oganezova G., Avetisyan N. The novel inhibitors of serine proteases. // Amino Acids. 2009. v.37. p.531−536.
81. Midura-Nawaczek K., Roszkowska-Jakimiec W., Lepieutsko I., Bruzgo I. Synthesis of benzylamides of dipeptides as potential inhibitors of plasmin. // Pharmazie. 2003. v. 10. p.687−689.
82. Markowska A., Midura-Nawaczek K., Bruzgo I. Low molecular peptides as potential inhibitors of plasmin. // Acta. Pol. Pharm. 2007. v.4. p.355−358.
83. Purwin M., Bruzgo I., Markowska A., Midura-Nawaczek K. Short peptides containing L-lysine and s-aminocaproic acid as potential plasmin inhibitors. // Pol. Pharmazie. 2009. v. l 1. p.765−767.
84. Wanaka K., Okamoto S., Horie N., Hijikata-Okonomiya A., Okamoto U., Naito T., Ohno N., Tsuda Y., Okada Y. Use of an active center-directed plasmin inhibitor elucidates the multiplicity of plasmin actions.
85. Nakamura K., Suzuki T., Hasegawa M., Kato Y., Sasaki H., Inouye K. Characterization of p-aminobenzamidine-based sorbent and its use forhigh-performance affmity-chromatography of trypsin-like proteases. // J. Chromat. A. 2003. v. 1009. p.133−139.
86. Lee E., Enomoto R., Takemura K., Tsuda Y., Okada Y. A selective plasmin inhibitor, trans-aminomethylcyclohexanecarbonyl-L-(0-picolyl)tyrosine-octylamide (YO-2), induces thymocyte apoptosis. // Biochem. Pharmacol. 2002. v.7. p.1315−1323.
87. Szende B., Okada Y., Tsuda Y., Horvath A., Bokonyi G., Okamoto S., Wanaka K., Keri G. A novel plasmin-inhibitor inhibits the growth of human tumor xenografts and decreases metastasis number. // In Vivo. 2010. v.5. p.281−286.
88. Okada Y., Tsuda Y., Tada M., Wanaka K., Hijikata-Okonomiya A., Okamoto U., Okamoto S. Development of plasma kallikrein selective inhibitors. // Biopolymers. 1999. v.51. p.41−50.
89. A. Differences in substrate and inhibitor sequence specificity of human, mouse and rat tissue kallikreins. // J. Biochem. 2004. v.380. p.775−781.
90. Мильготина E. И. Синтез хромогенных субстратов и ингибитора глутамилэндопептидаз с использованием субтилизина. // Дисс. канд. хим. наук. Москва. 2001.
91. Потетинова Ж. В. Стратегия биокаталитического синтеза модифицированных пептидов ингибиторов протеиназ. // Дисс. канд. хим. наук. Москва. 2000.
92. Reetz М. Т. S Synthesis and diastereoselective reactions of N, N-dibenzylamino aldehydes and related compounds. // Chem. Rev. 1999. v.99. p. l 121−1162.
93. McConnell R., Barnes G., Hyong C., Gunn M. Improved solid phase synthesis of C-terminal peptide aldehydes. // J. Med. Chem. 1990. v.33. p.86
94. Rooseboom M., Commandeur J. N. M., Vermeulen N. P. E. Enzyme-catalyzed activation of anticancer prodrugs. // Pharm. Rev. 2004. v.56. p.53−102.
95. Potetinova J. V., Voyushina T. L., Stepanov V. M. Enzymatic synthesis of peptidyl amino alcohols and peptidyl amino aldehydes-serine proteinase inhibitors. // Bioorg. Med. Chem. Lett. 1997. v.7. p.705−710.
96. Voyushina T. L., Potetinova J. V., Milgotina E. I., Stepanov V. M. Synthesis of peptide aldehydes via enzymatic acylation of amino aldehyde derivatives. // Bioorg. Med. Chem. Lett. 1999. v.7. p.2953−2959.
97. Schulze A., Giannis A. IBX-mediated conversion of primary alcohols and aldehydes to N-hydroxysuccinimide esters. // Adv. Synth. Catal. 2004. v.346. p.252−256.
98. Myers A.G., Zhong B. Movassagi M., Kung D. W. Synthesis of highly epimerizable N-protected a-amino aldehydes of high enantiomeric excess. // Tetrahedron Lett. 2000. v.41. p. 13 59
99. Saeed A., Ashraf Z. Sodium borohydride reduction of aromatic carboxylic acids via methyl esters.//J. Chem. Sci. 2006. v. 118. p.419−423.
100. Dale D. J., Dunn P. J., Golightly C., Hughes M. L., Levett P. C., Pearce A. K., Searle P. M., Ward G., Wood A. S. The chemical development of the commercial route to sildenafil: a case history. // Org. Proc. Res. Dev. 2000. v.4. p. 17−22.
101. Couladouros E. A., Moutsos V. I. A general synthetic route towards bastadins. Part 2: Synthesis of the western part of bastadins 4−16, and fully functionalized macrocycle of bastadin 12. // Tetrahedron Lett. 1999. v.40. p.7027−7030.
102. Shioiri T., Sasaki S., Hamada Y. Synthetic approach to microsclerodermins: construction of three building blocks. // ARKIVOC. 2003. ii. p.103−122.
103. Livingston D. In vitro and in vivo studies of ICE inhibitors. // J. Cell. Biochem. 1997. v.64. p. 19−26.
104. Reichert D., Kutscher B., Bang H., Brune K., Quinkert G., Schaible H.G. Specific immunophilin ligands as antiasthmatics and immunosuppressants. // Patent US 625 8815B 1. 2001.
105. Benedetti F., Berti F., Miertus S., Romeo D., Schillani F., Tossi A. Design, synthesis and preliminary evaluation of peptidomimetic inhibitors of FIIV aspartic protease with an epoxyalcohol core. // ARKIVOC. 2003. xiv. 140−154.
106. Sergeev M. E., Pronin V. B., Voyushina T. L. Procedure for the oxidation of (3-amino alcohols to a-aminoaldehydes. // Synlett. 2005. v. 18. p.2802−2804.
107. Kinugi S., Kobayashi I., Takano K., Murakami I. Effect of pressure on subtilisin catalysis: hydrolysis and peptide synthesis. // Bull. Chem. Soc. Jpn. 1996. v.69. p.3375−3380.
108. Kim J., Dordick J.S. Pressure affects enzyme function in organic media. // Biotech. Bioeng. 1993. v.42. p.772−776.
109. Lopez-Garcia M., Alfonso I., Gotor V. Chemoenzymatic approach to a ®-3,4-diaminobutanoic acid derivative with a suitable orthogonal protection for solid phase peptide synthesis. // Lett. Org. Chem. 2004. v. 1. p.254−256.
110. Белозерская Г. Г., Воюшина Т. Л., Макаров В. А., Неведрова О. Е., Сергеев М. Е., Сергеева О. А. Синтетические производные пептидов. // Патент РФ 2 341 532 С2. 2008.
111. Favaudon V. Radiation-induced crosslinking between poly (deoxyadenylic-deoxythymidylic acid) and tripeptides containing aromatic residues. // Int. J. Radiat. Biol. 1989. v.55. p.353−364.
112. Harrison J. G., Balasubramanian S. Synthesis and hybridization analysis of a small library of peptide-oligonucleotide conjugates. // Nucleic Acids Res. 1998. v.26. p.3136
113. Debethune L., Kohlhagen G., Grandas A., Pommier Y. Processing of nucleopeptides mimicking the topoisomerase I-DNA covalent complex by tyrosyl-DNA phosphodiesterase. // Nucleic Acids Res. 2002. v.30. p. 1198−1204.
114. Chaloin L., Vidal P., Lory P., Mery J., Lautredou N., Divita J., Heitz F. Design of carrier peptide oligonucleotide conjugate with rapid membranetranslocation. // Biochem. Biophys. Res. Commun. 2007. v.243. p.601−608.
115. Juliano R. L. Peptide-oligonucleotide conjugates for the delivery of antisense and siRNA. // Curr. Opin. Mol. Ther. 2005. v.7. p. 132−136.
116. Marchan V., Grandas A. Synthesis of peptide oligonucleotide conjugates by Diels-Alder cycloaddition in water. // Curr. Protoc. Nucleic Acids Chem. 2007. v.4. p.4.32.
117. Arar K., Aubertin A. M., Roche A. C., Monsigny M., Mayer R. Synthesis and antiviral activity of peptide-oligonucleotide conjugates prepared by using N"-(bromoacetyl)peptides. // Bioconjug. Chem. 1995. v.6. p.573−577.
118. Danieli B., Peri F., Roda G., Carrea G., Riva S. On the regioselectivity of the protease subtilisin towards the acylation of enantiomeric pairs of benzyl and naphthyl glycopyranosides. // Tetrahedron. 1999. v.55. p.2045−2060.
119. Maruyama T., Nagasawa S. I., Goto M. Enzymatic synthesis of sugar amino acid esters in organic solvents. // J. Biosci. Bioeng. 2002. v.94. p.357−361.
120. Liu C. F., Tarn J. P. Subtilisin-catalyzed synthesis of amino acid and peptide esters. Application in a two-step enzymatic ligation strategy. // Org. Lett. 2001. v.3. p.4157−4159.